Association Between Perioperative Low-Molecular-Weight Heparin vs Unfractionated Heparin and Clinical Outcomes in Patients With Cancer Undergoing Surgery

Akl, Elie A.; Kahale, Lara A

doi:10.1001/jama.2015.498

Cited by 5 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As for the heightened risk of deep vein thrombosis, should PICC recipients routinely receive pharmacological DVT prophylaxis in malignant neoplasms? Although more and more clinical trials were put into practice in cancer-related thrombosis [ 78 ], little suitable data for our meta-analysis could be collected in PICC-related area. Instead, 15 studies of CICCs with pharmacological deep vein thrombosis prophylaxis data were collected to make further stratification analysis about thrombosis by anticoagulant drugs, divided into warfarin group [ 24 , 25 , 30 , 31 , 39 , 43 , 50 , 60 ], heparin group [ 37 , 40 , 42 , 44 , 49 , 60 ], and other thrombolytic group [ 46 , 49 ].…”

Section: Discussionmentioning

confidence: 99%

Risk associated with central catheters for malignant tumor patients: a systematic review and meta-analysis

Hou

Pan

et al. 2018

Oncotarget

View full text Add to dashboard Cite

The risk of venous thrombosis and mortality associated with central catheter (PICC/CICC) for malignant tumor patients is not definite. So, we carried out a systematic review and meta-analysis to evaluate it. Among patients with comparing PICC with CICC, odds ratio (OR) or risk ratio (RR) was calculated with a random effect model meta-analysis. The result of the stratification analysis of 7 studies (PICC vs CICC) supported the theory that CICCs were associated with a decrease in the odds ratio of thrombosis compared with PICCs. 7 of 15 studies provided the information about the compared mortality rate of the patients. The result showed that CICCs were associated with a decrease in the odds ratio of thrombosis compared with PICCs (OR = 0.45, 95% CI:0.32–0.62, p < 0.0001, I2 = 0%,Tau2 = 0.00). Meta-analysis of 8 studies of 2639 patients showed that pharmacological deep vein thrombosis prophylaxis drugs could decrease the risk of mortality of malignant tumor patients with CICCs (RR = 0.58, 95% CI:0.48–0.71, Z = 5.32, p < 0.0001, I2 = 71%). We found that PICCs are associated with a raised risk of deep vein thrombosis, and pharmacological deep vein thrombosis prophylaxis drugs is a beneficial factor in decreasing the incidence of thrombosis, while warfarin may decrease the risk of mortality of malignant tumor patients with CICCs.

show abstract